vs
ANI PHARMACEUTICALS INC（ANIP）とBILL Holdings, Inc.（BILL）の財務データ比較。上の社名をクリックして会社を切り替えられます
BILL Holdings, Inc.の直近四半期売上が大きい（$414.7M vs $247.1M、ANI PHARMACEUTICALS INCの約1.7倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs -0.6%、差は11.8%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 14.4%）。BILL Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$103.8M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 13.3%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
BILLホールディングスは米国カリフォルニア州サンノゼを本拠地とする企業で、米国の中小企業向けにクラウド型の財務業務自動化ソフトウェアを提供している。傘下のBill.com Connectはホワイトラベル対応のエンドツーエンド支払い自動化プラットフォームで、金融機関がシングルサインオン式のオンライン企業銀行エコシステムの一部として導入可能である。
ANIP vs BILL — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $414.7M |
| 純利益 | $27.5M | $-2.6M |
| 粗利率 | — | 79.8% |
| 営業利益率 | 14.1% | -4.4% |
| 純利益率 | 11.1% | -0.6% |
| 売上前年比 | 29.6% | 14.4% |
| 純利益前年比 | 367.5% | -107.7% |
| EPS（希薄化後） | $1.14 | $-0.03 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $414.7M | ||
| Q3 25 | $227.8M | $395.7M | ||
| Q2 25 | $211.4M | $383.3M | ||
| Q1 25 | $197.1M | $358.2M | ||
| Q4 24 | $190.6M | $362.6M | ||
| Q3 24 | $148.3M | $358.4M | ||
| Q2 24 | $138.0M | $343.7M | ||
| Q1 24 | $137.4M | $323.0M |
| Q4 25 | $27.5M | $-2.6M | ||
| Q3 25 | $26.6M | $-3.0M | ||
| Q2 25 | $8.5M | $-7.1M | ||
| Q1 25 | $15.7M | $-11.6M | ||
| Q4 24 | $-10.3M | $33.5M | ||
| Q3 24 | $-24.2M | $8.9M | ||
| Q2 24 | $-2.3M | $7.6M | ||
| Q1 24 | $18.2M | $31.8M |
| Q4 25 | — | 79.8% | ||
| Q3 25 | — | 80.5% | ||
| Q2 25 | — | 80.8% | ||
| Q1 25 | — | 81.2% | ||
| Q4 24 | — | 81.6% | ||
| Q3 24 | — | 82.0% | ||
| Q2 24 | — | 81.0% | ||
| Q1 24 | — | 83.0% |
| Q4 25 | 14.1% | -4.4% | ||
| Q3 25 | 15.9% | -5.2% | ||
| Q2 25 | 6.6% | -5.8% | ||
| Q1 25 | 13.3% | -8.1% | ||
| Q4 24 | -2.3% | -6.0% | ||
| Q3 24 | -13.8% | -2.1% | ||
| Q2 24 | 3.7% | -6.5% | ||
| Q1 24 | 14.8% | -8.6% |
| Q4 25 | 11.1% | -0.6% | ||
| Q3 25 | 11.7% | -0.7% | ||
| Q2 25 | 4.0% | -1.8% | ||
| Q1 25 | 8.0% | -3.2% | ||
| Q4 24 | -5.4% | 9.3% | ||
| Q3 24 | -16.3% | 2.5% | ||
| Q2 24 | -1.7% | 2.2% | ||
| Q1 24 | 13.2% | 9.8% |
| Q4 25 | $1.14 | $-0.03 | ||
| Q3 25 | $1.13 | $-0.03 | ||
| Q2 25 | $0.36 | $0.02 | ||
| Q1 25 | $0.69 | $-0.11 | ||
| Q4 24 | $-0.45 | $-0.06 | ||
| Q3 24 | $-1.27 | $0.08 | ||
| Q2 24 | $-0.14 | $0.37 | ||
| Q1 24 | $0.82 | $0.00 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $1.1B |
| 総負債低いほど良い | — | $1.8B |
| 株主資本純資産 | $540.7M | $3.8B |
| 総資産 | $1.4B | $10.1B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.48× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $1.1B | ||
| Q3 25 | $262.6M | $1.1B | ||
| Q2 25 | $217.8M | $1.0B | ||
| Q1 25 | $149.8M | $1.0B | ||
| Q4 24 | $144.9M | $1.6B | ||
| Q3 24 | $145.0M | $853.5M | ||
| Q2 24 | $240.1M | $985.9M | ||
| Q1 24 | $228.6M | $952.5M |
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $914.8M | ||
| Q2 24 | — | $914.0M | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $540.7M | $3.8B | ||
| Q3 25 | $505.8M | $3.9B | ||
| Q2 25 | $436.8M | $3.9B | ||
| Q1 25 | $418.6M | $3.9B | ||
| Q4 24 | $403.7M | $3.8B | ||
| Q3 24 | $405.9M | $4.0B | ||
| Q2 24 | $455.8M | $4.1B | ||
| Q1 24 | $452.0M | $4.1B |
| Q4 25 | $1.4B | $10.1B | ||
| Q3 25 | $1.4B | $10.2B | ||
| Q2 25 | $1.3B | $10.1B | ||
| Q1 25 | $1.3B | $9.6B | ||
| Q4 24 | $1.3B | $9.7B | ||
| Q3 24 | $1.3B | $9.0B | ||
| Q2 24 | $920.8M | $9.2B | ||
| Q1 24 | $914.5M | $9.1B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.28× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $105.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $103.8M |
| FCFマージンFCF / 売上 | 11.8% | 25.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 0.4% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | — |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $378.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $105.3M | ||
| Q3 25 | $44.1M | $96.9M | ||
| Q2 25 | $75.8M | $83.8M | ||
| Q1 25 | $35.0M | $99.5M | ||
| Q4 24 | $15.9M | $78.7M | ||
| Q3 24 | $12.5M | $88.6M | ||
| Q2 24 | $17.4M | $78.6M | ||
| Q1 24 | $18.3M | $66.8M |
| Q4 25 | $29.1M | $103.8M | ||
| Q3 25 | $38.0M | $95.6M | ||
| Q2 25 | $71.8M | $81.0M | ||
| Q1 25 | $32.5M | $98.4M | ||
| Q4 24 | $13.5M | $78.3M | ||
| Q3 24 | $7.7M | $88.6M | ||
| Q2 24 | $13.0M | $78.4M | ||
| Q1 24 | $13.7M | $66.8M |
| Q4 25 | 11.8% | 25.0% | ||
| Q3 25 | 16.7% | 24.1% | ||
| Q2 25 | 34.0% | 21.1% | ||
| Q1 25 | 16.5% | 27.5% | ||
| Q4 24 | 7.1% | 21.6% | ||
| Q3 24 | 5.2% | 24.7% | ||
| Q2 24 | 9.4% | 22.8% | ||
| Q1 24 | 10.0% | 20.7% |
| Q4 25 | 0.5% | 0.4% | ||
| Q3 25 | 2.7% | 0.3% | ||
| Q2 25 | 1.9% | 0.7% | ||
| Q1 25 | 1.3% | 0.3% | ||
| Q4 24 | 1.3% | 0.1% | ||
| Q3 24 | 3.2% | 0.0% | ||
| Q2 24 | 3.2% | 0.1% | ||
| Q1 24 | 3.3% | 0.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 9.94× | ||
| Q2 24 | — | 10.35× | ||
| Q1 24 | 1.00× | 2.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
BILL
| Accounts Payable And Accounts Receivable Solutions | $185.9M | 45% |
| Spend And Expense Interchange Revenue | $166.5M | 40% |
| Interest On Funds Held For Customers | $39.5M | 10% |
| Embedded And Other Solutions | $22.8M | 5% |
